Radiotherapy Improves Survival in NSCLC After Oligoprogression on Immunotherapy: A Cohort Study.

ABSTRACT:

Introduction

The patterns of oligoprogression after first-line immune checkpoint inhibitors (ICIs) for metastatic NSCLC are yet to be well established. An increasing volume of data suggests that directed radiotherapy improves survival outcomes in patients with progression after ICIs.

Methods

A retrospective cohort study was performed on patients with metastatic NSCLC who had completed first-line programmed death-(ligand) 1 inhibitor therapy with or without chemotherapy at two high-volume cancer centers. We sought to characterize the frequency and location of oligoprogression and determine the overall survival (OS) after radiotherapy in this population.

Results

A total of 159 patients were included in the study. At first progression, 62 (39.0%) were classified as under

SUBMITTER: Brown LJ 

PROVIDER: S-EPMC11490415 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature